Updates from CheckMate 017 and CheckMate 057: Nivolumab, anti-PD1, for non-small cell lung cancer - European Medical Journal

Continue

Updates from CheckMate 017 and CheckMate 057: Nivolumab, anti-PD1, for non-small cell lung cancer

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Martin Reck, MD, PhD, from LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses an evaluation of overall health status in patients with advanced squamous non-small cell lung cancer (NSCLC) treated with nivolumab, an anti-PD-1 antibody, or docetaxel in CheckMate 017; and subgroup analyses and patient reported outcomes in patients with advanced non-squamous NSCLC treated with nivolumab or docetaxel in CheckMate 057.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.